Three-year results of iMODERN, a randomized, controlled clinical study involving 1,146 patients, provide evidence to widen minimally invasive treatment options for patients with acute myocardial ...

Indonesia can learn from the experiences of its regional peers in coming up with a localized strategy to achieve its targeted ...

TEMPO.CO, Jakarta - PT Kimia Farma Tbk posted a current-year loss of Rp234.1 billion from January to September 2025. This ...

Onsemi reported steady progress in its operational and manufacturing strategies during the third quarter of 2025, emphasizing ...